Stocks · Health care · Pharmaceutical Preparations

Amylyx Pharmaceuticals, Inc.

AMLX Clue Score40
United States Fiscal year ends December CIK 0001658551 Results filed 5 Nov 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Karen Firestone
21 May 2026
Director
Buy
3,800
$13.51
$51.34K
Karen Firestone
23 Dec 2025
Director
Buy
8,100
$12.45
$100.85K
Bernhardt G Zeiher
20 Mar 2025
Director
Buy
10,000
$3.70
$37.01K
James M Frates
12 Sep 2024
Chief Financial Officer
Buy
40,000
$2.53
$101.37K
Karen Firestone
5 Sep 2024
Director
Buy
50,000
$2.13
$106.59K
George M Milne Jr
3 Sep 2024
Director
Buy
100,000
$2.20
$219.80K
Daphne Quimi
15 May 2024
Director
Buy
2,250
$1.89
$4.25K
Daphne Quimi
14 May 2024
Director
Buy
2,750
$1.89
$5.18K
Karen Firestone
15 Dec 2023
Director
Buy
4,000
$14.97
$59.88K
Karen Firestone
16 Mar 2023
Director
Buy
1,000
$31.99
$31.99K
Viking Global Investors LP
11 Jan 2022
10% owner
Buy indirect
2,300,000
$19.00
$43.70M
Morningside Venture Investments Ltd
11 Jan 2022
10% owner
Buy
263,158
$19.00
$5.00M
Margaret Olinger
6 Jan 2022
Chief Commercial Officer
Buy
6,842
$19.00
$130.00K
George M Milne Jr
6 Jan 2022
Director
Buy
26,315
$19.00
$499.99K
Isaac Cheng
6 Jan 2022
Director
Buy
6,578
$19.00
$124.98K
Paul R. Fonteyne
6 Jan 2022
Director
Buy
3,947
$19.00
$74.99K

What was left out

Form 4 filings counted 178
Amendments (4/A) skipped 5
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 7
Sales straight out of an exercise 9
Sales at will 117
Transactions with no price 0
Shares from compensation/vesting 38,287,796
Sales filed before the plan box existed 42
History held since 10 Jan 2022